Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TGA Of Australia Eyes U.S. Counterpart's Avandia Decisions

This article was originally published in PharmAsia News

Executive Summary

Australia's Therapeutic Goods Administration, which already had ordered increased warnings on the labels for GlaxoSmithKline's Avandia (rosiglitazone) diabetes drug, is watching U.S. actions before taking further action

You may also be interested in...



GlaxoSmithKline Survives Technical Woes To Win US FDA Panel Nod For Belantamab

Benefits of the BCMA-directed antibody-drug conjugate outweigh its ocular risks in heavily pretreated multiple myeloma patients, Oncologic Drugs Advisory Committee says at the conclusion of a virtual meeting beset by technical problems.

US Appropriators Seek FDA Reports On ‘Toxic’ Cosmetic Chemicals, ‘Natural’ Cosmetics

The FDA must report to the House Appropriations Committee on any work toward defining “natural” cosmetics and on the health effects of talc, asbestos and lead in cosmetic products. The committee’s 2021 FDA spending bill report also cites concerns about skin-lightening products containing “dangerous levels of mercury and hydroquinone.”

Verrica’s Molluscum Product Set Back By FDA Usage Questions

Verrica got a complete response rather than approval for its drug/device combo for molluscum, but says the FDA only needs additional information on product changes for safe usage by clinicians.

UsernamePublicRestriction

Register

SC100339

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel